Category: Zacks Small Cap Research

123454630 / 456 POSTS
By David Bautz, PhDNASDAQ:CERCREAD THE FULL CERC RESEARCH REPORTBusiness UpdateCERC-801 Phase 1 Study CompleteOn April 29, 2019, Cerecor Inc. (NASDAQ:CERC) announced dosing has completed in the Phase 1 clinical trial of CERC-801 (D-galactose), which ...
By David Bautz, PhDNASDAQ:OPNTREAD THE FULL OPNT RESEARCH REPORTFinancial UpdateOn May 9, 2019, Opiant (NASDAQ:OPNT) announced financial results for the first quarter of 2019. The company recorded a total of $5.4 million in revenue for the three mont ...
By Beth Senko, CFANASDAQ:CASIREAD THE FULL CASI RESEARCH REPORTWe initiated coverage of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) with a target price of $8.17. CASI is establishing its footprint as a leading provider of high-quality proprietary, licen ...
By Brian Marckx, CFANASDAQ:MTBCREAD THE FULL MTBC RESEARCH REPORTQ1 2018 Results: MTBC, Inc (NASDAQ:MTBC) reported financial results for their first quarter 2019 and provided a business update. This was the third quarter with inclusion of Orion, the ...
By Brian Marckx, CFANASDAQ:CTSOREAD THE FULL CTSO RESEARCH REPORTQ1 2019 Update: Distributor Sales Take a Breather But Expected to Rebound. Direct Sales Remain Robust… CytoSorbents (NASDAQ:CTSO) reported financial results for their first quarter endi ...
By David Bautz, PhDNASDAQ:MTPREAD THE FULL MTP RESEARCH REPORTFinancial UpdateOn April 24, 2019, Midatech Pharma (NASDAQ:MTP) announced financial results for 2018. The company generated total gross revenue of £1.94 million, which included both collab ...
By David Bautz, PhDNASDAQ:MNOVREAD THE FULL MNOV RESEARCH REPORTBusiness UpdateReady to Move MN-166 into Phase 3 Trial in ALSOn April 15, 2019, MediciNova, Inc. (NASDAQ:MNOV) announced that following review of the protocol the U.S. Food and Drug Admi ...
By Lisa ThompsonNASDAQ:ABDCREAD THE FULL ABDC RESEARCH REPORTAlcentra Capital's (NASDAQ:ABDC) reported Q1 2019 earnings and again increased NAV. The new management team continues to execute on its strategy of rotating toward a larger middle market, s ...
By David Bautz, PhDNASDAQ:ORMPREAD THE FULL ORMP RESEARCH REPORTBusiness UpdateOramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a biotechnology company with a proprietary oral protein delivery platform technology. The lead development candidate is ORMD-0 ...
By John Vandermosten, CFAOTC:PMN.TO | OTC:ARFXFProMIS Neurosciences Inc. (OTC:PMN.TO) holds an enviable position in the drug development universe. The scientists leading the company have been able to merge chemistry, biology and physics to optimize d ...
123454630 / 456 POSTS